• Price (USD)272.81
  • Today's Change-0.24 / -0.09%
  • Shares traded544.59k
  • 1 Year change+36.06%
  • Beta0.8673
Data delayed at least 15 minutes, as of Dec 03 2021 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.

  • Revenue in USD (TTM)4.36bn
  • Net income in USD177.95m
  • Incorporated1989
  • Employees37.96k
  • Location
    ICON PLCSouth County Business Park, Dublin 18DUBLIN 00000IrelandIRL
  • Phone+353 12912000
  • Fax+353 12912700
  • Websitehttp://www.iconplc.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ICLR:NSQ since
PRA Health Sciences IncDeal completed24 Feb 202124 Feb 2021Deal completed30.77%11.11bn
Data delayed at least 15 minutes, as of Dec 03 2021 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Repligen Corporation592.66m118.88m14.53bn1.13k125.568.4794.5024.522.092.0910.4631.030.31882.096.66525,408.706.403.037.173.3558.5955.7320.0611.932.1613.770.1282--35.5334.39179.8845.0158.57--
Viatris Inc17.17bn-1.92bn14.75bn45.00k--0.69795.980.8594-1.91-1.9115.3217.480.39333.175.34381,515.60-4.400.5608-5.490.670834.3740.67-11.191.710.71522.230.52580.003.874.85-4,087.50---4.81--
BioMarin Pharmaceutical Inc.1.85bn-45.72m15.23bn3.06k--3.57238.288.24-0.25260.086410.0623.240.30470.65774.70604,309.30-0.7535-3.55-0.8494-4.1474.2077.95-2.47-10.713.03-3.650.2017--9.1815.89119.13---9.59--
10X Genomics Inc459.18m-455.35m15.41bn1.15k--19.22--33.55-4.23-,941.30-44.79---50.96--85.76---99.17--6.90-593.190.00--21.53---1,636.68------
PPD Inc5.88bn359.24m16.60bn26.00k47.17--25.522.821.001.0016.40-1.210.8996--3.33226,113.105.36--8.78--37.27--5.96----3.121.10--16.14--119.79------
BIO-TECHNE Corp984.55m176.56m17.92bn2.60k105.3610.9367.2418.214.334.3324.1441.740.45552.857.29378,673.808.107.248.597.7067.6666.7517.7917.663.1821.050.154238.2426.0413.28-38.746.0821.260.00
Charles River Laboratories Intl. Inc3.43bn396.60m18.03bn18.40k46.277.4327.235.267.727.7266.7548.090.558411.785.56186,201.106.576.687.737.9537.5837.2211.7710.581.225.940.54020.0011.5516.4944.5519.3821.37--
Alnylam Pharmaceuticals, Inc.749.31m-837.90m20.49bn1.45k--27.09--27.35-7.13-7.136.376.330.2211.528.41515,701.30-24.72-35.41-29.46-40.1383.25---111.82-368.564.22-7.790.3646--124.2864.353.14--40.29--
Catalent Inc4.18bn546.60m20.97bn17.30k38.465.2124.745.023.183.1824.3825.610.45995.194.46241,462.406.564.207.384.7834.1632.1414.268.332.995.750.49560.0029.2116.69205.7836.5337.50--
ICON PLC4.36bn177.95m22.21bn37.96k69.272.7959.675.103.943.9472.3797.900.4205--3.07276,918.901.7313.412.0919.5027.7233.254.1313.62--4.100.42660.00-0.304812.17-11.146.770.5273--
Horizon Therapeutics PLC2.96bn551.87m22.65bn1.81k43.145.0825.777.662.312.3112.7119.640.41144.553.992,119,900.007.681.348.661.6075.8167.8118.664.262.5510.210.36640.0069.2623.79-31.9858.0488.40--
AmerisourceBergen Corp.213.99bn1.54bn24.30bn42.00k15.81150.4411.760.11367.397.391,026.510.77614.2114.8212.365,094,973.003.040.163411.950.66143.172.890.72180.03650.566615.370.9196473.0912.697.82145.181.52-1.165.29
Gartner Inc4.54bn703.81m25.44bn15.60k38.4076.7127.635.608.068.0651.814.030.6564--4.62291,051.2010.172.7216.744.7669.2663.3215.504.17--9.190.88040.00-3.4413.6414.348.7212.71--
Seagen Inc1.75bn-332.75m27.56bn2.09k--8.71--15.79-1.85-1.859.5517.310.502.065.13834,519.10-9.53-0.4231-11.69-0.48983.5890.39-19.06-0.71684.20--0.00--137.3245.22486.81--43.82--
Data as of Dec 03 2021. Currency figures normalised to ICON PLC's reporting currency: US Dollar USD

Institutional shareholders

43.81%Per cent of shares held by top holders
HolderShares% Held
Massachusetts Financial Services Co.as of 30 Sep 20217.46m9.38%
WCM Investment Management LLCas of 30 Sep 20217.16m9.00%
Wellington Management Co. LLPas of 30 Sep 20215.05m6.34%
Comgest SAas of 30 Sep 20212.81m3.54%
ClearBridge Investments LLCas of 30 Sep 20212.36m2.97%
Janus Capital Management LLCas of 30 Sep 20212.24m2.81%
Boston Partners Global Investors, Inc.as of 30 Sep 20212.16m2.71%
Acadian Asset Management LLCas of 30 Sep 20211.99m2.50%
American Century Investment Management, Inc.as of 30 Sep 20211.95m2.45%
J.O. Hambro Capital Management Ltd.as of 30 Sep 20211.69m2.13%
More ▼
Data from 30 Sep 2021 - 30 Sep 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.